Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds JP Morgan Upgrades Bunge to Overweight

JP Morgan Upgrades Bunge to Overweight

JP Morgan analyst Thomas Palmer upgrades Bunge (NYSE:BG) from Neutral to Overweight.

byBenzinga Newsdesk

July 7, 2022

1 minute read

JP Morgan analyst Thomas Palmer upgrades Bunge (NYSE:BG) from Neutral to Overweight.

Analyst Ratings

Cracking The Code: Understanding Analyst Reviews For Dada Nexus

By Benzinga Insights

May 21, 10:00 AM

4 analysts have shared their evaluations of Dada Nexus (NASDAQ:DADA) during the recent three months, expressing a mix…

DADA

As Drugs Like Ozempic And Mounjaro Disrupt The Weigh Loss Market, Who Stands To Win — And Who Stands To Lose?

By Natan Ponieman

April 18, 2:42 PM

Ozempic, Wegovy and Mounjaro could very well have become the most sought-after weight-loss drugs of the past two…

LLY

Analyst Ratings

Expert Ratings for Opendoor Technologies

By Benzinga Insights

August 5, 11:13 AM

Opendoor Technologies (NASDAQ:OPEN) has observed the following analyst ratings within the last quarter:

OPEN

Natuzzi Q4 2022, FY Earnings Release Scheduled For April 5, Due To Certain Additional Procedures Needed For Its China JV

By Charles Gross

April 5, 5:09 AM

Natuzzi S.p.A. (NYSE: NTZ) announced today that the Company is postponing its release of the Company's 2022 fourth quarter and full-year financial results and conference call, originally scheduled for April 5, 2023 and April 6, 2023, respectively.

NTZ

JP Morgan Upgrades Bunge to Overweight

Related Posts

Cracking The Code: Understanding Analyst Reviews For Dada Nexus

As Drugs Like Ozempic And Mounjaro Disrupt The Weigh Loss Market, Who Stands To Win — And Who Stands To Lose?

Expert Ratings for Opendoor Technologies

Natuzzi Q4 2022, FY Earnings Release Scheduled For April 5, Due To Certain Additional Procedures Needed For Its China JV